Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ): 64 pipeline candidates · 13 upcoming catalysts · ~15 mo cash runway · 52 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.6 months
N/A
Lead: Phase 3
64 candidates
13 upcoming, next in ~56d
0 buys · 28 sells (180d)
A transparent, data-derived signal for Jazz Pharmaceuticals plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$14.3B
Cash
$1.8B
Quarterly Burn
$548.7M
Runway
14.6 mo
Revenue
$1.1B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (64 candidates)
| Drug | Phase |
|---|---|
| Asparaginase Erwinia chrysanthemi | Phase 2 |
| Cannabidiol | Phase 4 |
| Cannabidiol Oral Solution [Epidiolex] | Phase 4 |
| Cannabidivarin | Phase 4 |
| CBD-OS | Phase 2 |
| Cladribine | Phase 3 |
| Clofarabine | Phase 3 |
| CPX-351 | Phase 3 |
| Cytarabine | Phase 3 |
| Daunorubicin | Phase 3 |
Showing 10 of 64 candidates. Sign up for full pipeline.
Upcoming Catalysts (13)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
571
Total value held
$11.32B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,591,700 | $1.06B |
| vanguard capital management llc | 5,296,666 | $1.00B |
| vanguard portfolio management llc | 2,983,242 | $564.0M |
| fmr llc | 2,275,762 | $430.2M |
| franklin resources inc | 1,958,940 | $370.3M |
| dimensional fund advisors lp | 1,895,215 | $358.3M |
| state street corp | 1,891,646 | $357.6M |
| bank of new york mellon corp | 1,679,371 | $317.5M |
| fuller & thaler asset management, inc. | 1,676,142 | $316.9M |
| ameriprise financial inc | 1,608,476 | $304.1M |
Showing top 10 of 571 institutional holders of Jazz Pharmaceuticals plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Jazz Pharmaceuticals plc's pipeline?
Jazz Pharmaceuticals plc (JAZZ) has 64 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Jazz Pharmaceuticals plc's lead drug candidate?
Jazz Pharmaceuticals plc's most advanced tracked candidate is Asparaginase Erwinia chrysanthemi (Phase 2) for Newly.
What is Jazz Pharmaceuticals plc's next catalyst?
Jazz Pharmaceuticals plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezoliz" — expected August 13, 2026.
What is Jazz Pharmaceuticals plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Jazz Pharmaceuticals plc has approximately 14.6 months of cash runway.
What is Jazz Pharmaceuticals plc's market capitalization?
Jazz Pharmaceuticals plc's market capitalization is approximately $14.3B.
Get the full picture on Jazz Pharmaceuticals plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.